Form 4: Yubo Biotech President Converts Debt to Equity, Acquiring 42 Million Shares

Yubo International Biotech Ltd's President and 10% owner, Jun Wang, acquired 42 million Class A Common Stock shares at $0.05 each by converting company debt into equity.

Summary

• Jun Wang, President, Director, and 10% owner of Yubo International Biotech Ltd (YBGJ), acquired 42,000,000 shares of Class A Common Stock.
• The transaction occurred on July 23, 2025, at a price of $0.05 per share.
• The shares were acquired through a Securities Purchase Agreement, with the purchase price satisfied by the cancellation of certain indebtedness owed by Yubo International Biotech Ltd to Jun Wang.
• Following this transaction, Jun Wang beneficially owns 81,943,800 shares indirectly through FlyDragon International Limited, in which he holds a 100% equity interest.

Sentiment

Score: 7

Explanation: The conversion of debt to equity strengthens the company's balance sheet by reducing liabilities and increases insider ownership, which can be viewed positively for long-term alignment. However, the issuance of a large number of shares at a low price could lead to dilution for existing shareholders.

Positives

• Conversion of debt to equity strengthens the company's balance sheet by reducing liabilities.
• Increased insider ownership by a key executive and significant shareholder, potentially aligning management interests with long-term shareholder value.

Negatives

• Issuance of a large number of shares (42,000,000) at a low price ($0.05) could dilute existing shareholders.
• The transaction involves a related party, which warrants scrutiny for fair terms.

Industry Context

This Form 4 filing details an insider transaction specific to Yubo International Biotech Ltd and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• The transaction involves Jun Wang, who is the President, a Director, and a 10% owner of Yubo International Biotech Ltd, acquiring shares from the company.
• The shares were acquired from the Issuer in exchange for the cancellation of indebtedness owed by the Issuer to Jun Wang, making it a direct transaction between a key insider and the company.

Stakeholder Impact

• Shareholders: Potential dilution due to the issuance of 42,000,000 new shares, but also potential benefit from a strengthened balance sheet and increased insider alignment.
• Creditors (specifically Jun Wang): Debt converted to equity, changing his position from a creditor to an equity holder.

Key Dates

Recommendation

While the debt-to-equity conversion strengthens the company's balance sheet and increases insider alignment, the significant dilution from the issuance of 42 million shares at a low price of $0.05 warrants a cautious 'hold' stance. Investors should monitor the company's future financial performance and strategic initiatives to assess the long-term impact of this transaction.

Keywords

Yubo International Biotech Ltd, YBGJ, SEC Form 4, Insider Trading, Debt Conversion, Equity Issuance, Share Acquisition, Jun Wang, Director, President, 10% Owner, Related Party Transaction, Class A Common Stock